Lyell Immunopharma Files 8-K on Corporate Changes
Ticker: LYEL · Form: 8-K · Filed: Apr 1, 2025 · CIK: 1806952
| Field | Detail |
|---|---|
| Company | Lyell Immunopharma, Inc. (LYEL) |
| Form Type | 8-K |
| Filed Date | Apr 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-events, personnel-changes, regulation-fd
Related Tickers: LYEL
TL;DR
Lyell Immunopharma (LYEL) filed an 8-K detailing exit costs and executive departures. Watch for updates.
AI Summary
Lyell Immunopharma, Inc. filed an 8-K on March 27, 2025, reporting on cost associated with exit or disposal activities, departure of directors or certain officers, and compensatory arrangements. The filing also covers Regulation FD disclosures, indicating significant corporate events and personnel changes within the company.
Why It Matters
This 8-K filing signals potential restructuring or significant operational shifts within Lyell Immunopharma, which could impact its strategic direction and future performance.
Risk Assessment
Risk Level: medium — The filing indicates significant corporate events, including potential restructuring and executive changes, which can introduce uncertainty and risk.
Key Players & Entities
- Lyell Immunopharma, Inc. (company) — Registrant
- March 27, 2025 (date) — Date of earliest event reported
- 001-40502 (company) — SEC File Number
- 83-1300510 (company) — IRS Employer Identification No.
- 201 Haskins Way, South San Francisco, California 94080 (company) — Principal Executive Offices Address
- 650 695-0677 (company) — Registrant's Telephone Number
FAQ
What specific 'cost associated with exit or disposal activities' is Lyell Immunopharma reporting?
The filing does not specify the exact nature or amount of these costs, only that they are being reported under Item 1.01.
Which directors or officers have departed from Lyell Immunopharma?
The filing indicates departures under Item 5.02, but does not name the specific individuals in the provided text.
What are the details of the compensatory arrangements for certain officers mentioned in the filing?
The filing notes that information regarding compensatory arrangements is being reported under Item 5.02, but the specifics are not detailed in this excerpt.
What is the significance of the Regulation FD Disclosure mentioned?
This indicates that Lyell Immunopharma is making public disclosures to ensure broad dissemination of material non-public information, as required by Regulation FD.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing occurred on March 27, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 1, 2025 regarding Lyell Immunopharma, Inc. (LYEL).